Omnipod-5 A French Prospective Multicentric Study in Real World (Optimal-B)
← catalyst calendarNCT07317102 · readout ≤ 468 d
Sponsored by Insulet Corporation (industry) · PODD — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
152estimated
Sites
24
Country
France
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-03-16 | actual | When the study began enrolling |
| Primary completion | Nov 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Nov 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2026-01-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Diabetes
- Type 1 Diabetes
- Diabetes Mellitus
Intervention
- Device: Omnipod 5
Primary outcome
what the primary-completion date above is the date OFChange in the percentage of time in the 70 - 180 mg/dL range
measured Change in percentage of time in specified range between Baseline and 12-months following first initiation of automated mode
Permalink · PODD's whole pipeline · Catalyst calendar · Every registered study · What changed